Leading the Series A+ funding round, HEMEX is proud to announce that our portfolio company ASPIVIX not only secured $5M, but also received a large EUREKA-EUROSTARS grant, co-founded by Innosuisse. ASPIVIX will use the investment to enter the European and US market. Additionally, the company will invest in R&D to expand its existing product line and generate additional clinical data in the US.
HEMEX is a global provider of clinical research services to small and medium-sized life sciences companies in diverse therapeutic areas. By combining extensive clinical expertise, commitment to speed, and dedication to patient-centric approaches, HEMEX supports its clients to complete their clinical trials faster. Advancing healthcare and improving patient outcomes, HEMEX’s priority is ensuring patients can have access to lifesaving therapies within a short clinical journey. Through its subsidiaries, Hemex Germany GmbH and Hemex Benelux AV, the company can also secure project funding through different EU funds. For more information, visit https://hemex.ch/